Sengeløv, Lisa
Herlev Hospital · The Capital Region Pharmacy
3 papers on CoChat
Most cited papers
- Verified
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Kwon, E. D., Drake, C. G., Scher, H. I., Fizazi, K., Bossi, A., van den Eertwegh, A. J. M., Krainer, M., Houede, N., Santos, R., Mahammedi, H., et al. (2014) · The Lancet Oncology
Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment
Cited by 1,511
- Verified
Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer
Beer, T. M., Kwon, E. D., Drake, C. G., Fizazi, K., Logothetis, C., Gravis, G., Ganju, V., Polikoff, J., Saad, F., Humanski, P., et al. (2017) · Journal of Clinical Oncology
Prostate Cancer Treatment and ResearchCancer Immunotherapy and Biomarkers
Cited by 765
- Verified
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors
Fizazi, K., Drake, C. G., Beer, T. M., Kwon, E. D., Scher, H. I., Gerritsen, W. R., Bossi, A., den Eertwegh, A. J. M. V., Krainer, M., Houede, N., et al. (2020) · European Urology
Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment
Cited by 185
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free